PT  - JOURNAL ARTICLE
AU  - VÉGVÁRY, ZOLTÁN
AU  - DARÁZS, BARBARA
AU  - PACZONA, VIKTOR
AU  - DOBI, ÁGNES
AU  - REISZ, ZITA
AU  - VARGA, ZOLTÁN
AU  - FODOR, EMESE
AU  - CSERHÁTI, ADRIENN
AU  - OLÁH, JUDIT
AU  - KIS, DÁVID
AU  - BARZÓ, PÁL
AU  - HIDEGHÉTY, KATALIN
TI  - Adaptive Radiotherapy for Glioblastoma Multiforme – The Impact on Disease Outcome
AID  - 10.21873/anticanres.14425
DP  - 2020 Aug 01
TA  - Anticancer Research
PG  - 4237--4244
VI  - 40
IP  - 8
4099  - http://ar.iiarjournals.org/content/40/8/4237.short
4100  - http://ar.iiarjournals.org/content/40/8/4237.full
SO  - Anticancer Res2020 Aug 01; 40
AB  - Background/Aim: To study the changes of glioblastoma multiforme during chemoradiotherapy (CRT) and to evaluate the impact of changes on dosimetry and clinical outcomes. Patients and Methods: Forty-three patients underwent volumetric imaging-based replanning. Prognostic factors and gross tumor volume changes in relation to overall survival and the effect of adaptive replanning were statistically analyzed. Results: Patients with total tumor removal, with shorter time to CRT (<27 days), with methylated O-6 methylguanine DNA methyltransferase and good performance status (>60%) had better survival. Tumor shrinkage in 24 patients resulted in improved survival compared to 19 in whom tumor was unchanged or progressed (25.3 vs. 11.1 months, p=0.04). Adapted planning target volume allowed a reduction in irradiated volume, while increasing survival (12.06 vs. 28.98 months, p=0.026). Conclusion: Tumor response during CRT has significant impact on the outcome. Adaptation of the planning target volume to the tumor changes proved to be beneficial and warrants further investigation.